A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination

References

• Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12:671–675. doi:10.1002/hep.1840120409
   PubMed Web of Science ®Google Scholar
• Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148–156. doi:10.1007/s00535-004-1519-2
   PubMed Web of Science ®Google Scholar
• Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol. 2005;20:752–758. doi:10.1111/j.1440-1746.2005.03800.x
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tokumoto Y, Joko K, et al. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2019;49:136–146. doi:10.1111/hepr.13278
   PubMed Web of Science ®Google Scholar
• Tani J, Morishita A, Sakamoto T, et al. Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: all Kagawa Liver Disease Group Study. Oncol Lett. 2020;19:2205–2212. doi:10.3892/ol.2020.11341
   PubMed Web of Science ®Google Scholar
• Ide T, Koga H, Nakano M, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int. 2019;13:293–301. doi:10.1007/s12072-019-09939-2
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–36. doi:10.1002/hep.21669
   PubMed Web of Science ®Google Scholar
• Okamoto H, Kurai K, Okada S, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes. Virology. 1992;188:331–341. doi:10.1016/0042-6822(92)90762-E
   PubMed Web of Science ®Google Scholar
• Tanaka A, Uegaki S, Kurihara H, et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol. 2007;13:5180–5187. doi:10.3748/wjg.v13.i39.5180
   PubMed Web of Science ®Google Scholar
• Hirakawa M, Ikeda K, Arase Y, et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med. 2008;47:1637–1643. doi:10.2169/internalmedicine.47.1087
   PubMed Web of Science ®Google Scholar
• Arase Y, Kobayashi M, Suzuki F, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57:964–973. doi:10.1002/hep.26087
   PubMed Web of Science ®Google Scholar
• Asahina Y, Tsuchiya K, Nishimura T, et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58:1253–1262. doi:10.1002/hep.26442
   PubMed Web of Science ®Google Scholar
• Nagaoki Y, Imamura M, Akita H, et al. The risk of hepatocellular carcinoma development after HCV eradication are similar between patients with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One. 2017;12:e0182710. doi:10.1371/journal.pone.0182710
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Suzuki F, Fujiyama S, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol. 2017;89:476–483. doi:10.1002/jmv.24663
   PubMed Web of Science ®Google Scholar
• Tahata Y, Sakamori R, Urabe A, et al. Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. Hepatol Res. 2020;50:1118–1233. doi:10.1111/hepr.13547
   PubMed Web of Science ®Google Scholar
• Abe K, Wakabayashi H, Nakayama H, et al. Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis. PLoS One. 2020;15:e0243473. doi:10.1371/journal.pone.0243473
   PubMed Web of Science ®Google Scholar
• Kanda T, Lau GKK, Wei L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019;13:649–661. doi:10.1007/s12072-019-09988-7
   PubMed Web of Science ®Google Scholar
• Ikeda K, Kawamura Y, Kobayashi M, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2017;62:2932–2942. doi:10.1007/s10620-017-4739-z
   PubMed Web of Science ®Google Scholar
• Nagaoki Y, Imamura M, Nishida Y, et al. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: comparison with interferon-based therapy. J Med Virol. 2019;91:650–658. doi:10.1002/jmv.25352
   PubMed Web of Science ®Google Scholar
• Sugiura A, Joshita UT, Yamazaki T, et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat. 2018;25:1462–1471. doi:10.1111/jvh.12973
   PubMed Web of Science ®Google Scholar
• Kawal F, Kramer JR, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153:996–1005. doi:10.1053/j.gastro.2017.06.012
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157:1264–1278. doi:10.1053/j.gastro.2019.07.033
   PubMed Web of Science ®Google Scholar